DOCSLIB.ORG

Medical Laboratory Technician (Chemistry and Urinalysis).(AFSC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Laboratory Technician (Chemistry and Urinalysis).(AFSC DOCUMENT RESUME ED 272 711 CE 044 810 AUTHOR Thompson, Joselyn H. TITLE Medical Laboratory Technician (Chemistry and Urinalysis). (AFSC 92470). INSTITUTION Air Univ., Gunter AFS, Ala. Extension Course Inst. PUB DATE 85 NOTE 441p.; Supersedes ED 224 891. PUB TYPE Guides - Classroom Use Materials (For Learner) (051) EDRS PRICE MF01/PC18 Plus Postage. DESCRIPTORS *Allied Health Occupations Education; Behavioral Objectives; Biomedical Equipment; *Chemical Analysis; Correspondence Study; Equipment Utilization; *Laboratory Procedures; *Laboratory Technology; Learning Activities; *Medical Laboratory Assistants; *Medical Technologists; Military Personnel; Military Training; Postsecondary Education; Quality Control IDENTIFIERS Air Force; Military Curriculum Materials; *Urinalysis ABSTRACT This four-volume student text is designed for use by Air Force personnel enrolled in a self-study extension course for medical laboratory technicians. Covered in the individual volumes are medical laboratory administration and clinical chemistry (career opportunities, general laboratory safety and materials, general medical laboratory administration, basic chemistry, solutions, photometry and spectrophotometry, automation, quality control in collection and handling of specimens); laboratory procedures in clinical chemistry (body metabolism; proteins, carbohydrates, and enzymes; liver and kidney function tests; gastric analysis;special chemistry tests; toxicology) and laboratory procedures in urinalysis (general considerations, renal functions, physical characteristics of urine, microscopic examination, and chemical examination). Each volume in the set contains a series of lessons, exercises at the end of each lesson, a bibliography, and answers to the exercises. Volume review exercises are also included. (MN) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. *********************************************************************** MEDICAL LABORATORY TECHNICIAN (CHEMISTRY AND URINALYSIS) (AFSC 92470) BEST COPY AVAILABLE U.S. DEPARTMENT OF EDUCATION Office of F ducahonai Research and Improvemenr EDUCATIONAL RESOURCES INFORMATION CENTER (ERIC) docfle,l has been reproduced as rece,ved from the Person or 0,garezatfon orej.nating ft o MmOr changes have teen rnade to improve reproducfion quahly po,nts of v,ewor opOlonsstat.,dfl thi5 dOc u ment do not necessardy represent oftfc.al OE RI pos.hon or policy Extension Course Institute Air University ECI COURSE MATERIALS SHIPPING LIST EF FECTIVE DATE DURSE NUMBER COURSE TITLE MEDICAL LABCRATORY TECHN IC IAN CI-THATS TRY AND URINALYS IS) 40 41 (AFSC 92470) 2 Jun upon receiving your .uurav package. and INSTRUCIIONS: 7.14,7 lollowgmaterials areneeded to oornplete this course. Check this list immediately any materials are missing or incorrect (nI4mberl don't match ), notify ECIimmediately. Else the EC1 Form 17 for this purpose, and be sure to include it- corresponth,nce separately Youridentification number,address, course and volume number, and VRE form designation (if a VRE is involved). Send all from your answer ghee t. INVENTORY CONTROL VRE ANSWER DESIGNATION OR TITLE SHEET ITEM TYPE NUMBER IDENTIFICATION 3 VOI, VOL 1, Introduction to Medical Laboratory 9041101851_0 Administration ari to Clinical Chemistry 4 VR VOLUME RF:\/ I EW EXERC E (VOL 1_) 90411fn24 904110124 5 VoL VOL 2, Laboratory Procedures in Clinical 90411027608 Chemistry (Part I) 6 VIRE VOLUME REVIEW EXERC E (VOL 2) 904110223 904110223 7 VOL VOL 3, Laboratory Procedures in Clinical 90411037608 Chemistry (Part II) 8 VRE VOLUME REVIEW EXERCISE (VOL 3) 904110323 904110323 9 VOL VOL 4, Laboratory Procedures in Urinalysis 90411047608 10 VRE VOLUME REVIEW EXERCISE (VOL 4) 904110423 904110423 NOTE : DI RECT AN Y QU T1(3\IS OR COMM1I\T IS RK LAT TNG `TO ACCURACY OF 'TEXTUAL MATER HUE AUTOVCN 736-4471. SPECIAL 1\10TE: DISREGARD ME MSC 90470 PRINTEDavThEcalmOF ME TEX' IS . M IS DC IS FOR AIRMEN CN UPGRADE TRAMING TO AFS C 92470 ONLY. SEP: REVI,RSE SIDE FOR ADDITP)NAL INSTRUCTIONS. 25 PREVIOUS EDITION WILL 1.1E USED. ECI JUNFORM 8 4 Page I. of 3 LIST OF CHANGES OURSE NUMDED ALSO, )041) CAREER FIELDS, POLICIES, PROCEDURES AND EQUIPMENT CHANGE. FFECTtVE DATE OF ERRORS OCCASIONALLY GET INTO PRINT. THE FOLLOWING FILMS UPDATE ANI) CORRECT YOUR COURSE MATERIALS. PLEASE MAKE THE INDICATED CHANGES. IPPS.111 ;PECIAL NUPE: THROJT TriE TEXTS AND VOLUME REV1E4 EXERCISE; FOR THIS COURSI.:, (1LVilE FFR;T 3 DIGUIS OF ALL AFSCS FROM 904 TO 924. 1. CHANGES FOR THE TEXT:VOLUME I a. Page 67, col 2, line 6 fr bot: Change "octet" to "completion." b. Page 84, Exercise (052)-1.(10): Change "buffered" to "unbuffered." c. Page ,ver 011-1(7): Change "f" to "c." d. Page 160, answer 029-3: Change "Take a few . result t)ort" to "Correct." Answer 033-7: Change "No" to "Yes" and delete "not" in both places. e. Par! 161, answer 042-10: Change "oxygen" to "hydrogen." f. 1-3e 163, answer 057-(1): Change "1" to "k." g. Page 165, answer 074-8: After "as" add "those." Col 1, line 11fr bot, answer 075-6: Change "serum" to "the cells." 2. CHANGES FOR THE TEXT: VOLUME 2 a. Page 52, col 2, last line: Change "LDH" to "LAP." b. Page 53, col 1, lines 1 and 3: Change "LDH" to "LAP." 3. CHANGE FOR PHE TEXT VOLUME 3 Page 56, col 1, line 12: Change "facilities" to "fatalities." Col line 12: Change "423" to "433." 4. CHANGES PT.% THE ,c1; ME REVIEW EXERCISE: VOLUME 1 a. Page 6, question 34: In the stem of the question, change ",-,ervic . to "service; however, this was not expected to cover the manning shortage in the blood bank." b. Question 10 is no longer scored and need not be answered. 5. CHANGES FOR THE VOLUME REVIEW EXERCISE: VOLUME 2 a. Pale 3, question 15, choice a: Change "incerase" to "increase." Choice b: Change the second "decrease" to "increase." b. page 5, querltion 31: in the stem of the question, delete ", srum biliruhin is high and." c. Page 6, question 38: In the stem of the question, change "Frog" to "Gror." d. Page 9, question 72, choice a: Change "phenlphethalein" to "phenolphthalein." Choice c: Change "methly" to "methyl." e. Page 11, question 81: In the stem of the question, change "catalyze" to "catalyzes." 4 Continuation Sheet for ECI Form 25 Page 2 of 3 LIST OF CHANGES 1URS NUM ALSO, ,0411 CAREER FIELDS, POLICIES, PROCEDURES AND EQUIPMENT CHANGE. 'FECTIVE DATE OF ERRORS OCCASIONALLY GET INTO PRINT. THE FOLLOWING ITEMS UPDATE AND ITPTILIAT) CORRECT YOUR COURSE MATERIALS. PLEASE MAKE THE INDICATED CHANGES. CHANGES FOR THE VOLUME REVIEW EXERCISE: VOLUME 2 (Continued) f. Page 13, question 105, choices a and c: Change "exalacetate" to "oxalacetate." g. The following questions are no longer scored and need not be answered: 7 and 81. ChANGF:'; FOR THE VOLUME REVIEW EXT-RCESE: VOLUME 3 a. rage 2, quetion 5, choice a: Change "ureas" to "urea." b. Page 3, question 11: In the stri of the question, change "text." to "I-est." Qurstion .4: In the stem of the question, change "insufficiently" to "insufficiency." c. 7, question 44, choice c: Change "nitrose" to "nitroso."Question 50: In the itam of guestion, change "materia" to "material." d. Page 9, question 64, choice d: Change "dodium hydrosulfide." to "sodium Iydrosulfite." Questf.m 68: In the stem of the question, change "gives a positive tPst" 'will cause the iminadiate appearance of a sliight turbidity." e. The following questions are no longer scored and need not be answered: 19 and 65. 7. CHANGES FOR THE VOLUME REVIEW EXERCE3E: VOLUME 4 a. Page 3, question 15: In the stem of the question, change "pres!-.;ure" to "17.2sence." b. Page 5, question 31: In the stem of the question, after "solution" add a comm. c. Page 6, question 40: In the stem of the question, remove underline from "describing" and under line "transudation." d. Page 10, question 80, choice c: Change "Abermaver" to "Obermayer."Qua;tion 84, :thoice 6: "orthotolodine" to "orthotolidine." P. Page 11, question 88: Change "(115)" to "(638)." t. Question 72 is no longer scored and need not be answered. rowlAMMI l'ontinuation Sheet for ECI Form 25 Page 3 of 3 t- Prepared by CMSgt Joselyn H. Thompson (AUTOVON: 736-2809) Reviewed by Elmore C. Hall Edited by Joyce Wagner Anderson SCHOOL OF HEA1 T-rt CA SCIENCES, t -t-C) SHEPPARD AIR rAtr:F j TEXAS EXTENSION COURSE INSTITUTE (AU) GUNTER AIR FORCE STATION, ALABAMA 36118-5643 7 Preface THE AIR FORCE laboratory technician should possess and demonstrate the technical ability to effectively deliver quality laboratory service. Quality laboratory service is essential to the accurate diagnosis and treatment of patients. Laboratory technicians, today and in the future, should use good supervisory and administrative skills for efficient management of the medical laboratory. This volume provides you with a background of basic information so that together with your on-the-job training and experience, you should easily make the transition from the 5-level specialist to the 7-level technician. This CDC 90411 is the first of three career development courses for the 92470 specialty. Chapter 1 of this volume introduces the mission and capabilities of Air Force clinical laboratories and guidelines in career progression. In chapter 2, you will review current principles of laboratory materiel and general laboratory safety. Chapter 3 reviews general laboratory administration, emphasizing laboratory ethics and interpersonal relations, laboratory reports, and accreditation program. Chapters 4 and 5 cover a review of basic chemistry and the nature and concentration of laboratory solutions. Chapter 6 is about basic principles of photometry and spectrophotometry. Chapter 7 reviews principles, techniques, and instruments used in automation. Chapter 8 concludes with further principles and techniques for collection and handling laboratory specimens and a review of quality control in the clinical laboratory. For your convenience in the course and future reference, the Appendixes contain the duties and responsibilities of your specialty, a Periodic Chart, and a summary of general laboratory formulae. Code numbers appearing on figures are for preparing agency identification only.
Load more

Recommended publications
  • Silver Iodate 1
    SILVER IODATE 1 Silver Iodate a,c-Biladienes with exocyclic rings have been utilized in silver iodate–zinc acetate mediated cyclization.7,8 The reaction of a,c-biladienes bearing six-membered carbocyclic rings with silver AgIO 3 iodate in dimethylformamide followed by demetalation with 5% sulfuric acid in trifluoroacetic acid affords the isolated porphyrin in [7783-97-3] IO3Ag (MW 282.77) 12% yield (eq 3). The syntheses of petroporphyrin bearing a seven- 9 InChI = 1/Ag.HIO3/c;2-1(3)4/h;(H,2,3,4)/q+1;/p-1/fAg.IO3/ membered exocyclic ring, such as C32 15,17-butanoporphyrin qm;-1 and its 3-methyl homolog,10 have been reported by Lash and John- InChIKey = YSVXTGDPTJIEIX-YIVJLXCRCQ son (eq 4).8 Treatment of a,c-biladiene salts with silver iodate and zinc acetate affords desired petroporphyrins via oxidative cycliza- (reagent used as a versatile oxidative amidation and cyclization tion in good yields under mild conditions.5 However, attempts to component) cyclize a,c-biladienes bearing exocyclic rings under other condi- Physical Data: mp >200 ◦C; d 5.53 g cm−3. tions such as copper(II) chloride in dimethylformamide or cop- Solubility: soluble in aqueous ammonia; practically insoluble in per(II) acetate in pyridine result in only trace amounts of the water (0.3 g L−1 at 10 ◦C). cyclized petroporphyrins due to the geometry enforced on the Form Supplied in: white crystalline powder; commercially avail- tetrapyrrolic intermediate by the carbocyclic ring conformation.11 able. It has been shown that the silver iodate–zinc acetate mediated Handling, Storage, and Precautions: irritant; light sensitive; conditions can increase the stability of the cyclizing tetrapyrroles, causes ignition with reducing agents or combustibles; store in resulting in improvement of the cyclization yield.12 cool and dry conditions in well-sealed containers; handle in fume hood.
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • Reproducibility of Silver-Silver Halide Electrodes
    U. S. DEPARTMENT OF COMMERCE NATIONAL BUREAU OF STANDARDS RESEARCH PAPER RP1183 Part of Journal of Research of the National Bureau of Standards, Volume 22, March 1939 REPRODUCIBILITY OF SILVER.SILVER HALIDE ELECTRODES 1 By John Keenan Taylor and Edgar Reynolds Smith ABSTRACT Tests of the reproducibility in potential of the electrolytic, thermal-electrolytic, and thermal types of silver-silver chloride, silver-silver bromide, and silver-silver iodide electrodes, in both acid and neutral solutions, are reported. All of these silver-silver halide electrodes show an aging effect, such that freshly prepared electrodes behave as cathodes towards electrodes previously aged in the solution. They are not affected in potential by exposure to light, but the presence of oxygen disturbs the potentials of the silver-silver chloride and silver-silver bromide elec­ trodes in acid solutions, and of the silver-silver iodide electrodes in both acid and neutral solutions. Except in the case of the silver-silver iodide electrodes, of which the thermal-electrolytic type seems more reliable than the electrolytic or the thermal type, the equilibrium potential is independent of the type, within about 0.02 mv. CONTENTS Page I. Introduetion_ __ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ 307 II. Apparatus and materials_ _ _ _ _ _ _ _ _ _ _ _ _ __ __ _ _ ___ _ _ ____ _ _ _ _ ___ _ _ _ _ 308 III.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,039,940 Perrault Et Al
    US0060399.40A United States Patent (19) 11 Patent Number: 6,039,940 Perrault et al. (45) Date of Patent: Mar. 21, 2000 54) INHERENTLY ANTIMICROBIAL 5,563,056 10/1996 Swan et al.. QUATERNARY AMINE HYDROGEL WOUND 5,599.321 2/1997 Conway et al.. DRESSINGS 5,624,704 4/1997 Darouiche et al.. 5,670.557 9/1997 Dietz et al.. 75 Inventors: James J. Perrault, Vista, Calif.; 5,674.561 10/1997 Dietz et al.. Cameron G. Rouns, Pocatello, Id. 5,800,685 9/1998 Perrault. FOREIGN PATENT DOCUMENTS 73 Assignee: Ballard Medical Products, Draper, Utah 92/06694 4/1992 WIPO. WO 97/14448 4/1997 WIPO. 21 Appl. No.: 09/144,727 OTHER PUBLICATIONS 22 Filed: Sep. 1, 1998 I. I. Raad, “Vascular Catheters Impregnated with Antimi crobial Agents: Present Knowledge and Future Direction,” Related U.S. Application Data Infection Control and Hospital Epidemiology, 18(4): 63 Continuation-in-part of application No. 08/738,651, Oct. 28, 227–229 (1997). 1996, Pat. No. 5,800,685. R. O. Darouiche, H. Safar, and I. I. Raad, “In Vitro Efficacy of Antimicrobial-Coated Bladder Catheters in Inhibiting 51) Int. Cl." .......................... A61K31/785; A61F 13/00 Bacterial Migration along Catheter Surface,” J. Infect. Dis., 52 U.S. Cl. ..................................... 424/78.06; 424/78.08; 176: 1109-12 (1997). 424/78.35; 424/78.37; 424/443; 424/445 W. Kohen and B. Jansen, “Polymer Materials for the Pre 58 Field of Search ..................................... 424/443, 445, vention of Catheter-related Infections.” Zbl Bakt., 283: 424/78.06, 78.07, 78.08, 78.35, 78.37 175-186 (1995).
    [Show full text]
  • United States P Patented July 18, 1972
    3,677,840 United States P Patented July 18, 1972 iodide of the invention is obtained in a highly active form 3,677,840 ideally suited for nucleating purposes. PYROTECHNICS COMPRISING OXDE OF SILVER The metathesis reaction proceeds substantially accord FOR WEATHERMODIFICATION USE ing to the following equation: Graham C. Shaw, Garland, and Russell Reed, Jr. Brigham City, Utah, assignors to Thiokol Chemical Corporation, Bristol, Pa. No Drawing. Filed Sept. 18, 1969, Ser. No. 859,165 In accordance with the invention, the pyrotechnic com int, C. C06d 3/00 o position comprises, by weight, the cured product produced U.S. C. 149-19 5 Claims by mixing and curing together from about 0.5% to about 10 20% of oxide of silver; from about 2% to about 45% of an alkali iodate present in about a stoichiometric amount ABSTRACT OF THE DISCLOSURE relative to the amount of oxide of silver present in the A pyrotechnic composition which upon combustion composition; from about 25% to about 75% of a solid in produces mixed silver halide nuclei for use in influencing organic oxidizer selected from the perchlorates and the weather comprises a composition made by curing a mix 5 nitrates of ammonium and of Group I-A and Group II-A ture comprising silver oxide, an alkali iodate, an alkali metals of the Periodic Table; and from about 10% to perchlorate and a curable oxygenated or fluorinated or about 20% of a curable, fluid polymer binder for pyro ganic liquid polymer binder. The composition burns technic compositions, especially a combined-halogen-rich smoothly to provide by metathesis a mixture of silver or combined-oxygen-rich polymer binder, preferably a halides as substantially the only solid or condensed phase 20 polyester-urethane terminated with amine or hydroxyl reaction products, and leaves substantially no residue.
    [Show full text]
  • Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
    bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters.
    [Show full text]
  • Risks to Health and the Environment Related to the Use of Mercury Products
    Ref. Ares(2015)4242228 - 12/10/2015 Risks to Health and the Environment Related to the Use of Mercury Products Final Report prepared for The European Commission, DG Enterprise by Risk & Policy Analysts Limited, Farthing Green House, 1 Beccles Road, Loddon, Norfolk, NR14 6LT Tel: 01508 528465 Fax: 01508 520758 Email: [email protected] Web: www.rpaltd.co.uk RPA REPORT - ASSURED QUALITY Project: Ref/Title J372/Mercury Approach: In accordance with the Contract, Scoping Meeting with the Commission and associated discussions Report Status: Final Report Authors: Dr P Floyd & P Zarogiannis, RPA Dr M Crane, Crane Consultants Prof S Tarkowski, Nofer Institute of Occupational Medicine (Poland) Prof V Bencko, Charles University of Prague Approved for Issue by: Ms M Postle, Director Date: 9 August, 2002 If printed by RPA, this report will be on chlorine free, 100% recycled paper. Risk & Policy Analysts EXECUTIVE SUMMARY Overview Mercury and its compounds are hazardous materials which may pose risks to people and to the environment. This report presents an assessment of the risks associated with the use of mercury in a range of products. The key requirements of the study were: • to identify usage of mercury in dental amalgam, batteries, measuring instruments (such as thermometers and manometers), lighting, other electrical components and other lesser uses; • to review data used to evaluate the toxicity of mercury and mercury compounds to humans and to the environment; • to derive predicted environmental concentrations (PECs) associated with use of the products under consideration and compare with those associated with other sources of mercury; and • to characterise the associated risks.
    [Show full text]
  • Survey of Mercury and Mercury Compounds
    Survey of mercury and mercury compounds Part of the LOUS-review Environmental Project No. 1544, 2014 Title: Authors and contributors: Survey of mercury and mercury compounds Jakob Maag Jesper Kjølholt Sonja Hagen Mikkelsen Christian Nyander Jeppesen Anna Juliana Clausen and Mie Ostenfeldt COWI A/S, Denmark Published by: The Danish Environmental Protection Agency Strandgade 29 1401 Copenhagen K Denmark www.mst.dk/english Year: ISBN no. 2014 978-87-93026-98-8 Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, the Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor COWI or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of mercury and mercury compounds Contents Preface ...................................................................................................................... 5 Summary and conclusions ......................................................................................... 7 Sammenfatning og konklusion ................................................................................ 14 1.
    [Show full text]
  • United States Patent Office Patented Aug
    3,751,562 United States Patent Office Patented Aug. 7, 1973 2 3,751,562 chlorophene, with a gelled oil. The base for these com MEDICATED GELLIED OLS Joseph Nichols, Princeton, N.J., assignor to Princeton positions is preferably a mineral oil gelled by at least one Biomedix incorporated, Princeton, N.Y. polyoxyethylated fatty acid alcohol ether. No Drawing. Continuation-in-part of abandoned applica Accordingly, it is a primary object of the present in tion Ser. No. 28,124, Apr. 13, 1970. This application vention to provide a topical medicament which is free Sept. 22, 1972, Ser. No. 291,239 of the aforementioned and other such disadvantages. Ent. C. A61k 9/06, 27/00 It is another primary object of the present invention U.S. C. 424-45 Clains to provide a carrier for a topical medicament which is clear, Water-soluble, aesthetically pleasing, and non-irri O tating. ABSTRACT OF THE DISCLOSEURE It is another object of the present invention to provide Medicated gelled oils suitable for topical application are a topical antiseptic composition which is relatively in disclosed. The gelled oils which form an ointment base are expensive to manufacture and easy to apply. mineral oils gelled with at least one polyoxyethylated It is still another object of the present invention to pro fatty acid alcohol ether. The base can be compounded 5 vide an antiseptic composition containing iodine, which With any conventional topical medicament for use as a composition is non-irritating, easy to apply, and has a germicide, fungicide, or anesthetic. long-lasting effect. Yet another object of the present invention is to pro This application is a continuation-in-part of co-pending vide an antiseptic composition containing thimerosal, application Ser.
    [Show full text]
  • Maine Remedial Action Guidelines (Rags) for Contaminated Sites
    Maine Department of Environmental Protection Remedial Action Guidelines for Contaminated Sites (RAGs) Effective Date: May 1, 2021 Approved by: ___________________________ Date: April 27, 2021 David Burns, Director Bureau of Remediation & Waste Management Executive Summary MAINE DEPARTMENT OF ENVIRONMENTAL PROTECTION 17 State House Station | Augusta, Maine 04333-0017 www.maine.gov/dep Maine Department of Environmental Protection Remedial Action Guidelines for Contaminated Sites Contents 1 Disclaimer ...................................................................................................................... 1 2 Introduction and Purpose ............................................................................................... 1 2.1 Purpose ......................................................................................................................................... 1 2.2 Consistency with Superfund Risk Assessment .............................................................................. 1 2.3 When to Use RAGs and When to Develop a Site-Specific Risk Assessment ................................. 1 3 Applicability ................................................................................................................... 2 3.1 Applicable Programs & DEP Approval Process ............................................................................. 2 3.1.1 Uncontrolled Hazardous Substance Sites ............................................................................. 2 3.1.2 Voluntary Response Action Program
    [Show full text]
  • Chemical Names and CAS Numbers Final
    Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number C3H8O 1‐propanol C4H7BrO2 2‐bromobutyric acid 80‐58‐0 GeH3COOH 2‐germaacetic acid C4H10 2‐methylpropane 75‐28‐5 C3H8O 2‐propanol 67‐63‐0 C6H10O3 4‐acetylbutyric acid 448671 C4H7BrO2 4‐bromobutyric acid 2623‐87‐2 CH3CHO acetaldehyde CH3CONH2 acetamide C8H9NO2 acetaminophen 103‐90‐2 − C2H3O2 acetate ion − CH3COO acetate ion C2H4O2 acetic acid 64‐19‐7 CH3COOH acetic acid (CH3)2CO acetone CH3COCl acetyl chloride C2H2 acetylene 74‐86‐2 HCCH acetylene C9H8O4 acetylsalicylic acid 50‐78‐2 H2C(CH)CN acrylonitrile C3H7NO2 Ala C3H7NO2 alanine 56‐41‐7 NaAlSi3O3 albite AlSb aluminium antimonide 25152‐52‐7 AlAs aluminium arsenide 22831‐42‐1 AlBO2 aluminium borate 61279‐70‐7 AlBO aluminium boron oxide 12041‐48‐4 AlBr3 aluminium bromide 7727‐15‐3 AlBr3•6H2O aluminium bromide hexahydrate 2149397 AlCl4Cs aluminium caesium tetrachloride 17992‐03‐9 AlCl3 aluminium chloride (anhydrous) 7446‐70‐0 AlCl3•6H2O aluminium chloride hexahydrate 7784‐13‐6 AlClO aluminium chloride oxide 13596‐11‐7 AlB2 aluminium diboride 12041‐50‐8 AlF2 aluminium difluoride 13569‐23‐8 AlF2O aluminium difluoride oxide 38344‐66‐0 AlB12 aluminium dodecaboride 12041‐54‐2 Al2F6 aluminium fluoride 17949‐86‐9 AlF3 aluminium fluoride 7784‐18‐1 Al(CHO2)3 aluminium formate 7360‐53‐4 1 of 75 Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number Al(OH)3 aluminium hydroxide 21645‐51‐2 Al2I6 aluminium iodide 18898‐35‐6 AlI3 aluminium iodide 7784‐23‐8 AlBr aluminium monobromide 22359‐97‐3 AlCl aluminium monochloride
    [Show full text]